Peptide News Digest

#July-2026

2 stories

Regulatory · View digest

FDA Peptide Compounding Reclassification Status Check Ahead of July 23-24 PCAC — Seven Peptides (BPC-157, TB-500, Epitalon, Semax, KPV, MOTs-C, Emideltide/DSIP) Pending 503A Bulks-List Decision

With EASL and ASCO dominating the clinical-data cycle, the FDA peptide-compounding regulatory track continues moving toward the July 23-24, 2026 Pharmacy Compounding Advisory Committee (PCAC) meeting. Twelve peptides came off the FDA Category 2 'significant safety risk' bulks list effective April 23, 2026; seven of those (BPC-157, TB-500, KPV, MOTs-C on Day 1; Emideltide/DSIP, Semax, Epitalon on Day 2) advance to the July PCAC for affirmative 503A bulks-list inclusion. A second PCAC before end of February 2027 reviews five more (GHK-Cu injectable, Melanotan II, Cathelicidin LL-37, Dihexa, PEG-MGF). Removal from Category 2 does not yet permit compounding — that requires the affirmative PCAC recommendation plus FDA final determination (6-12 month timeline). The parallel 503B bulks-list proposal excluding semaglutide, tirzepatide, and liraglutide closes public comments June 29. The compounded-semaglutide shipment volume is down 90% year-over-year per the BSR Intelligence briefing as the regulatory vise tightens on the gray-market segment.

Industry · View digest

Umbrella Labs Epitalon Peptide Documentation Update (May 25): Reference-Material Standardization for Research Pipeline Ahead of July 23-24 PCAC Review

Umbrella Labs announced Monday May 25 a documentation and traceability update for its Epitalon peptide reference material, provided strictly for laboratory developmental research use. The update is part of the company's standardization initiative focused on identity-field consistency, record continuity, and reproducibility — the same template Umbrella applied to Dihexa on May 19. Epitalon (Glu-Asp-Gly-Lys) is a four-amino-acid peptide originally derived from the bovine pineal gland by Vladimir Khavinson and studied as a senescent-cell modulator and telomerase activator. The peptide is on the FDA's PCAC review docket for July 23-24, 2026 — Day 2 alongside Emideltide/DSIP and Semax — for potential 503A bulks-list inclusion. Reference-material standardization across the research-peptide supply chain is the soft regulatory signal that compounding pharmacies and supply networks are preparing for the PCAC review window.